English

Nomination Committee for the IRRAS 2023 Annual General Meeting

Report this content

The Nomination Committee for IRRAS AB for the Annual General Meeting 2023 has now been appointed, based on the shareholder structure on 30 September 2022.

Stockholm, December 6, 2022 – According to the principles for the appointment of the Nomination Committee in IRRAS AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members that represent the three largest shareholders after the end of the third quarter of the year before the AGM is held, together with the chairman of the company’s Board of Directors. The largest shareholders refer to the registered shareholders or otherwise known shareholders after the end of the third quarter.

The composition of the Nomination Committee has now been established, and IRRAS today announced that the Nomination Committee for the annual general meeting 2023 consists of the following persons:

  • Christer Hellström, chairman of the nomination committee, representing Bacara Holdings Limited
  • Philippe Audi, representing Spetses Investments Limited
  • Yana Vlasova, representing Lexington Holding Assets Limited
  • Marios Fotiadis, Chairman of the Board of IRRAS AB

The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2023 and on IRRAS’ website, www.irras.com.

Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to nomination@irras.com (subject “Nomination Committee”) or by letter posted to IRRAS AB, Attn: IRRAS Nomination Committee, Vasagatan 16, 111 20 Stockholm, Sweden.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on December 6, 2022 at 8:30 (CET).

Subscribe